Compare · ARGX vs SOPH
ARGX vs SOPH
Side-by-side comparison of argenx SE (ARGX) and SOPHiA GENETICS SA (SOPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and SOPH operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $48.63B, about 127.5x SOPH ($381.3M).
- Over the past year, ARGX is up 20.7% and SOPH is up 70.9% - SOPH leads by 50.2 points.
- SOPH has been more active in the news (48 items in the past 4 weeks vs 3 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 13 for SOPH).
- Company
- argenx SE
- SOPHiA GENETICS SA
- Price
- $783.89+0.27%
- $5.23-0.29%
- Market cap
- $48.63B
- $381.3M
- 1M return
- +5.40%
- +2.55%
- 1Y return
- +20.68%
- +70.92%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2021
- News (4w)
- 3
- 48
- Recent ratings
- 25
- 13
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
SOPHiA GENETICS SA
Sophia Genetics SA, a cloud-based software-as-a-service platform that enables healthcare institutions to get insights from their data. The company offers SOPHiA DDM for solid tumors. Sophia Genetics SA was founded in 2012 and is based in Saint-Sulpice, Switzerland.
Latest ARGX
- argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
- SEC Form 6-K filed by argenx SE
- argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
- SEC Form 6-K filed by argenx SE
- argenx announces Annual General Meeting of Shareholders on May 6, 2026
- SEC Form 20-F filed by argenx SE
- SEC Form 6-K filed by argenx SE
- argenx upgraded by Deutsche Bank
- SEC Form 6-K filed by argenx SE
- argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
Latest SOPH
- Chief Medical Officer Menu Philippe sold $24,089 worth of Ordinary Shares (5,000 units at $4.82) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 261,388 units (SEC Form 4)
- SEC Form 4 filed by Van Well Daan
- SEC Form 4 filed by Xu Zhenyu
- SEC Form 4 filed by Valente Manuela
- SEC Form 4 filed by Menu Philippe
- SEC Form 4 filed by Camblong Jurgi
- SEC Form 4 filed by Muken Ross
- SEC Form 4 filed by Puylaert Kevin
- SOPHiA GENETICS to Announce Financial Results for First Quarter 2026 on May 5, 2026
- SEC Form 144 filed by SOPHiA GENETICS SA